Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) EBIT Margin (2016 - 2025)

Cytosorbents' EBIT Margin history spans 15 years, with the latest figure at 92.68% for Q4 2025.

  • Quarterly results put EBIT Margin at 92.68% for Q4 2025, up 12978.0% from a year ago — trailing twelve months through Dec 2025 was 4.87% (up 4134.0% YoY), and the annual figure for FY2025 was 4.87%, up 4135.0%.
  • EBIT Margin for Q4 2025 was 92.68% at Cytosorbents, up from 30.17% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 92.68% in Q4 2025 to a low of 111.17% in Q3 2022.
  • The 5-year median for EBIT Margin is 55.73% (2021), against an average of 56.44%.
  • The sharpest move saw EBIT Margin tumbled -6665bps in 2021, then surged 12978bps in 2025.
  • Year by year, EBIT Margin stood at 88.68% in 2021, then increased by 24bps to 67.69% in 2022, then crashed by -60bps to 108.54% in 2023, then surged by 66bps to 37.1% in 2024, then skyrocketed by 350bps to 92.68% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 92.68%, 30.17%, and 37.59% for Q4 2025, Q3 2025, and Q2 2025 respectively.